ArticleUpdates in surgery2025
Glisson's capsule invasion as a risk factor of multifocal intrahepatic recurrence after hepatectomy for hepatocellular carcinoma: a retrospective single-center cohort study.
Article in Updates in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRisk factors for intrahepatic recurrence after hepatectomy for HCC are incompletely understood. Intrahepatic lymphatic drainage through the Glisson's sub-serosal system may represent a pathway favoring intrahepatic spread of cancer cells. This study investigates the prognostic role of Glisson's capsule invasion by hepatocellular carcinoma (HCC) after hepatectomy.
methodsOf 192 patients undergoing curative hepatectomy at a single institution between 2010 and 2023, 84 met the inclusion criteria and were retrospectively analyzed. Primary endpoints of intra-hepatic recurrence rate and pattern, and secondary survival endpoints were analyzed between patients with microscopic presence vs. absence of Glisson's capsule invasion by HCC.
resultsMicroscopic tumor invasion of the Glisson's capsule was found in 39 (46.4%) patients. After a median follow-up of 36 months, 44 (52.4%) patients developed intrahepatic recurrent disease, and most cases (n = 32, 72.7%) occurred as early recurrence (within 15 months). Glisson's capsule invasion was associated with higher overall (73.5% vs. 56.8%, p = 0.114) and early (55.9% vs. 35.1%, p = 0.079), recurrence rates, and more frequently demonstrated a multifocal pattern of tumor recurrence (75.0% vs. 40.0%, p = 0.019). Glisson's capsule invasion was the only histopathologic risk factor of multifocal relapse (odds ratio: 4.5, p = 0.022). Kaplan-Meier survival estimates returned an unfavorable median DFS (15.1 vs. 47.6 months, p = 0.034) and OS (50.4 vs. 76.3 months, p = 0.074) in case of Glisson's capsule invasion.
conclusionsGlisson's capsule invasion by the primary HCC is associated with a pattern of multifocal intrahepatic recurrence and unfavorable survival. Further studies are required to validate its prognostic role and surgical implications.
Indexed as
Identifiers
40770151What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.